



32 **Abstract**

33 **Background:** Latest clinical data on treatment on coronavirus disease 2019 (COVID-19) indicated  
34 that older patients and those with underlying history of smoking, hypertension or diabetes mellitus  
35 might have poorer prognosis of recovery from COVID-19. We aimed to examine the relationship  
36 of various prevailing population-based risk factors in comparison with mortality rate and case  
37 fatality rate (CFR) of COVID-19.

38 **Methods:** Demography and epidemiology data which have been identified as verified or  
39 postulated risk factors for mortality of adult inpatients with COVID-19 were used. The number of  
40 confirmed cases and the number of deaths until April 16, 2020 for all affected countries were  
41 extracted from Johns Hopkins University COVID-19 websites. Datasets for indicators that are  
42 fitting with the factors of COVID-19 mortality were extracted from the World Bank database. Out  
43 of about 185 affected countries, only top 50 countries were selected to be analyzed in this study.  
44 The following seven variables were included in the analysis, based on data availability and  
45 completeness: 1) proportion of people aged 65 above, 2) proportion of male in the population, 3)  
46 diabetes prevalence, 4) smoking prevalence, 5) current health expenditure, 6) number of hospital  
47 beds and 7) number of nurses and midwives. Quantitative analysis was carried out to determine  
48 the correlation between CFR and the aforementioned risk factors.

49 **Results:** United States shows about 0.20% of confirmed cases in its country and it has about 4.85%  
50 of CFR. Luxembourg shows the highest percentage of confirmed cases of 0.55% but a low 2.05%  
51 of CFR, showing that a high percentage of confirmed cases does not necessarily lead to high CFR.  
52 There is a significant correlation between CFR, people aged 65 and above ( $p = 0.35$ ) and diabetes  
53 prevalence ( $p = 0.01$ ). However, in our study, there is no significant correlation between CFR of  
54 COVID-19, male gender ( $p = 0.26$ ) and smoking prevalence ( $p = 0.60$ ).

55 **Conclusion:** Older people above 65 years old and diabetic patients are significant risk factors for  
56 COVID-19. Nevertheless, gender differences and smoking prevalence failed to prove a significant  
57 relationship with COVID-19 mortality rate and CFR.

58 **Keywords:** Coronavirus, COVID-19, risk, epidemiology, fatality, age, diabetes

59  
60  
61  
62  
63  
64  
65  
66  
67  
68

## 69 Introduction

70 On February 11, 2020, WHO renamed the highly contagious respiratory disease, caused by severe  
71 acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as COVID-19 (1). On March 11, 2020,  
72 due to the alarming levels of spread and severity of COVID-19 worldwide and by the alarming  
73 levels of inaction, WHO has characterized the COVID-19 situation as a pandemic (2). As the  
74 COVID-19 outbreak continues to evolve, researchers are learning more about SARS-CoV-2 every  
75 day, including the fact that it can be transmitted from symptomatic, pre-symptomatic and  
76 asymptomatic people infected with COVID-19 (3). Studies have shown that COVID-19 is  
77 primarily transmitted from symptomatic people who are in close contact through respiratory  
78 droplets, by direct contact with infected persons or by contact with contaminated objects and  
79 surfaces (1). Fever, tiredness and dry cough are the most common symptoms in symptomatic  
80 COVID-19 patients (4).

81 Even though there is limited information regarding risk factors for this severe disease, there are  
82 evidences showing a few clear risk factors, including age and underlying medical conditions, might  
83 be at higher risk for severe illness from COVID-19 (5,6). Other risk factors that have been  
84 discussed included gender, Bacillus Calmette-Guerin (BCG) vaccination, smoking and malaria  
85 prevalence (7,8). Older people have a higher risk due to the decreasing function of the age-  
86 dependent lymphocytes resulting in their increased susceptibility to COVID-19 disease (9). In  
87 addition, a study shows that there is a higher percentage of death among patients aged over 65  
88 years (62%) than patients aged below 65 years old (37%) (10). Furthermore, male gender is  
89 commonly observed in COVID-19 patients (73%) according to a retrospective study done on 113  
90 deceased patients (11).

91 Another risk factor for COVID-19 mortality is in patients with existing comorbidities. A study by  
92 Guan et al. shows that COVID-19 are more commonly seen in patients with hypertension, diabetes,  
93 cardiovascular disease and a history of smoking (12). Not only were these patients susceptible to  
94 the disease, they also had a higher chance of obtaining poor health outcomes after Immediate Care  
95 Unit (ICU) admission and may lead to death (10). Moreover, a study on the correlation between  
96 COVID-19 mortality and BCG vaccination suggested that early BCG vaccination could help to  
97 decrease the mortality rate (7). Other than that, malaria prevalence is also another risk factor of  
98 COVID-19 mortality. According to the research conducted by Spencer, there is a higher number  
99 of COVID-19 cases reported in countries with low malaria prevalence than countries that had  
100 higher malaria prevalence (13). Apart from addressing risk factors, there are also parameters that  
101 may affect the COVID-19 mortality rate such as shortage of staff, lack of medical supply or  
102 equipment, insufficient hospital beds and the country's health expenditure.

103 As of end of April 2020, SARS-CoV-2 virus has resulted in more than 3.1 million infections and  
104 over 217,000 deaths globally (1). As COVID-19 has become a global pandemic issue,  
105 implementation of suitable interventions will be needed for the public, healthcare professionals  
106 and patients and to ensure all sectors to work together cohesively and efficiently. Even though  
107 COVID-19 originates from coronavirus, the SARS-CoV-2 has very different severity and contagion  
108 characteristics and much still needs to be learned about it. Thus, it is imperative to evaluate the  
109 relationship of postulated or verified risk factors with COVID-19 mortality. It is absolute crucial  
110 to evaluate the risk factors of mortality among patients infected with COVID-19 at population  
111 level. By validating the relationship, patients with COVID-19 can be treated more aggressively  
112 than those without the risk factor. The findings of the current study provide a clinical picture of

113 COVID-19 case fatality rate in top 50 affected countries. A predictive model of COVID-19  
114 population infection rate and case fatality rate that will increase clinicians' attention for this highly  
115 fatal and morbid disease was developed. These findings consolidate the evidence of crucial risk  
116 factors that front liners that need to prioritise to decrease the COVID-19 mortality globally.

117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143

## 144 **Methods**

### 145 **Data extraction**

146 Demography and epidemiology data which have been identified as verified or postulated risk  
147 factors for mortality of adult inpatients with COVID-19 were used. The data were obtained from  
148 those published in the World Bank and Johns Hopkins University COVID-19 websites. The  
149 number of confirmed cases and the number of deaths for all affected countries were extracted from  
150 the latter (14). Datasets for indicators that are fitting with the factors of COVID-19 mortality were  
151 extracted from the World Bank database (15). Data extracted for this study is up until April 16,  
152 2020. All data acquired were exported in excel format and arranged according to country rankings  
153 with the top having the highest number of confirmed cases as of April 16, 2020 and the bottom  
154 having the least. Out of about 185 affected countries, only top 50 countries were selected to be  
155 analyzed in this study.

156 The following seven variables were included in the analysis, based on data availability and  
157 completeness: 1) proportion of people aged 65 above, 2) proportion of male in the population, 3)  
158 diabetes prevalence, 4) smoking prevalence, 5) current health expenditure, 6) number of hospital  
159 beds and 7) number of nurses and midwives.

### 160 **Data analysis**

161 For each country, the percentage of confirmed COVID-19 case per country was calculated by  
162 dividing the number of confirmed COVID-19 cases by the total population for each country. Also,  
163 CFR was calculated by dividing the number of deaths related to COVID-19 by the confirmed  
164 COVID-19 cases. Bar graphs are plotted to illustrate both measures.

165 Regression analysis was conducted to determine the risk factors of CFR for COVID-19. For this  
166 analysis, few variables (CFR and number of hospital beds) were standardized due to differences  
167 in scale and very large range. Standardization was done by subtracting each value by the mean and  
168 then dividing it with the standard deviation. Also, some variables (diabetes prevalence, current  
169 health expenditure, and number of nurses and midwives) were divided into four equal categories  
170 (i.e. in quartiles). All analyses were conducted using Microsoft Excel and R (ver. 3.6.0). A *p*-value  
171  $< 0.05$  was considered as statistically significant.

172

173

174

175

176

177

178

179

180

181 **Results**

182 Information of 2,017,444 confirmed COVID-19 cases and 137,166 deaths from each of the 50 top  
183 countries (Supplementary Information) were extracted. This constitutes about 93.3% and 92.8%  
184 of the global confirmed cases and deaths on the data collection date (April 16, 2020).

185 **Case Fatality Rate (CFR) and mortality rate of COVID-19 in the top 50 countries**

186 From data extracted up until April 16, 2020, the United States (US) reported to have the highest  
187 number of total confirmed cases and the highest total number of deaths of 639,733 cases and  
188 31,002 cases respectively. Despite that, the US shows about 0.20% (Table 1) of confirmed cases  
189 in its country and it has about 4.85% of CFR (Table 1), indicating a moderate death rate of COVID-  
190 19 in comparison to other countries. Luxembourg, ranked 47<sup>th</sup> in the list of top 50 COVID-19  
191 countries, shows the highest percentage of confirmed cases of 0.55% (Table 1) but a low 2.05%  
192 of CFR (Table 1), showing that a high percentage of confirmed cases does not necessarily lead to  
193 a high CFR. This is due to variations in number, transmission rate and severity of the disease  
194 regardless of the rankings. Hence, it is important to evaluate the possible factors that can affect the  
195 increase of COVID-19 mortality rate globally.

196 **Relationship between the different risk factors and COVID-19 CFR**

197 The proportion of people aged 65 and above has a significant association with CFR ( $p = 0.04$ ,  
198 Table 2). The  $\beta$  coefficient of 4.70 tells us that for every 1-unit increase in the proportion of people  
199 aged 65 years, the CFR increases by 4.7 units. This relationship is illustrated in Figure 1, where  
200 CFR sharply increases when the proportion of people aged 65 years is 0.15 and above. Also, there  
201 is a certain association between diabetes prevalence and CFR. When compared to countries with  
202 low prevalence (31. – 5.5%), those with highest prevalence (9.67-19.9%) have lower CFR by 0.97  
203 units ( $p = 0.01$ , Table 2). However, no significant association was observed when including both  
204 variables (proportion of people aged 65 and above and diabetes prevalence) into the multiple  
205 regression analysis.

206

207

208

209

210

211

212

213

214

215

216

217

## 218 Discussion

219 There are still a lot of unknown regarding the disease COVID-19. There is a steep learning curve  
220 about the virus, and this could take a couple of years to work out. However, we are not completely  
221 in the dark when it comes to risk factors.

222 Studies have shown that age is a clear risk factor for severe COVID-19 disease and thus, resulting  
223 in death. This has been confirmed by our study where the proportion of people aged 65 and above  
224 has shown a significant correlation with CFR. This indicates that countries with a higher proportion  
225 of people aged 65 and above may result in higher COVID-19 mortality rate. Bhatraju et al. (2020)  
226 has shown that in Seattle, the US reported more than 60% of COVID-19 deaths in patients aged  
227 65 years and above than those who are younger than 65 years old (10). Verity et al. (2020) has  
228 shown that the case fatality rate for those under age 60 was 1.4% while the fatality rate increases  
229 drastically to 4.5% for those people aged over 60 years old (6). This shows that the older the  
230 population, the higher the fatality rate. For those 80 years old and over, COVID-19 appears to have  
231 a 13.4% fatality rate (6). Furthermore, deceased patients were found to be at an average age of 68  
232 years old while recovered patients to be at an average age of 51 years old (11). These studies show  
233 that COVID-19 disproportionately impacts certain groups, and older people is one of the  
234 vulnerable groups. There is no one reason to this; it is believed that immune system declines with  
235 age. An increase of deficiency in T-cell and B-cell function and overproduction of type 2 cytokines  
236 as age increases (9). This may increase the viral replication and extend the duration of pro-  
237 inflammatory responses leading to poor health results (9). Older people tend to have more  
238 underlying conditions that may also be risk factors for severe COVID-19 (6,12).

239 Even though there is no significance shown between COVID-19 CFR and the male gender, it is  
240 important to note that differences in gender may play a role in severity of COVID-19. There are  
241 studies that have shown COVID-19 affecting more males than females (16–18). This could be  
242 due to males having more underlying health risk factors than the female population or the fact that  
243 males tend to engage in more risky health-relatable behaviours, such as greater rates of smoking  
244 and drinking alcohol (19). Genetics and differences in immune response can be explanations to  
245 this phenomenon too.

246 Studies have shown that many of the severe COVID-19 patients also have underlying medical  
247 conditions, such as diabetes and cardiovascular diseases (11,20). Our study has confirmed that  
248 there is indeed a certain association between diabetes prevalence and CFR. However, it is  
249 important to note that according to our study, diabetes prevalence may be an “unreliable” variable  
250 as it was shown that countries with high diabetes prevalence have lower COVID-19 CFR than  
251 countries with low diabetes prevalence. Further investigation is needed to define the actual  
252 association between diabetes prevalence and COVID-19. Although smoking prevalence has shown  
253 no significant association with COVID-19, it cannot be assumed that there is no correlation  
254 between other co-morbidities and COVID-19 CFR since not all factors were considered in this  
255 study, such as hypertension and cardiovascular diseases (18). Patients with existing comorbidities,  
256 including hypertension, diabetes, cardiovascular disease and history of smoking, seems to be  
257 associated with COVID-19 more severely (12). With reference to a retrospective study of 113  
258 deceased patients from COVID-19, 48% of the patients had chronic hypertension and 14% of them  
259 had cardiovascular diseases (11). In addition to that, COVID-19 patients who have hypertension  
260 were closely associated with poor health outcomes after hospital admission. This may be due to  
261 factors such as vascular aging, reduced renal function and medication interactions (21).

262 It is important to note that everyone is responsible in controlling this COVID-19 pandemic,  
263 slowing the rate of transmission and hence successfully flattening the curve. An increase in  
264 COVID-19 cases can affect the country's economy. It is necessary for some countries may need  
265 more supplies than others to cater all sick patients, and thus increasing the health expenditure of  
266 the country (2). Some of the medical supplies include Personal Protective Equipment (PPE),  
267 mechanical ventilators, COVID-19 testing kits and Extracorporeal Membrane Oxygenation  
268 (ECMO). Due to surge of demand on health care system, countries with low income and poor  
269 healthcare infrastructure suffer the most (12). However, in our study, current health expenditure  
270 does not significantly correlate to an arising COVID-19 CFR. One possible explanation to this is  
271 the various levels of well-preparedness plans implemented in the country to handle this pandemic  
272 situation. These include availability of medicines or medical supplies to treat COVID-19 patients,  
273 availability of suitable places to quarantine or self-isolate these patients, number of healthcare  
274 professionals and a strategized interventions, such as social distancing, quarantine, isolation  
275 actions and proper management, for the patients and public to flatten the curve and to reduce  
276 healthcare burden.

277 Even though there is no significant correlation, this does not indicate health expenditure is not  
278 important. Hospital beds is an example of hospital expenditures, and is important in the  
279 improvement of hospitals by making adjustments in volume-based to fulfill healthcare demands  
280 (2). Improvement in hospital capacity is necessary to accommodate any future pandemic situations  
281 (22). Despite the insignificant correlation to COVID-19 CFR, accessibility to adequate hospital  
282 beds for COVID-19 patients can potentially affect the CFR as the number of beds required depends  
283 on the number of confirmed cases in each country. Apart from hospital beds, other medical  
284 supplies such as PPE and mechanical ventilators must be sufficient as they are the key equipment  
285 for frontline healthcare workers (23–25). Evidence of high numbers of infections and deaths  
286 among healthcare workers due to lack of PPE were reported in Italy (23). In the US, recent  
287 estimates have suggested that the estimated ventilators needed is ranging from several hundred  
288 thousand to a million, far more than what are currently available (23). It is difficult to estimate the  
289 exact number of ventilators needed as it depends on the number, transmission rate and severity of  
290 the disease in each country. Although there is no significant relationship between the number of  
291 nurses and midwives and CFR, number of healthcare professionals is a crucial factor in the  
292 COVID-19 outbreak. The reason to this insignificance can be due inadequate data obtained as the  
293 data collected are only numbers of nurses and midwives. It is important to take into account the  
294 numbers of other healthcare professionals. Physicians and nurses who had no disease expertise  
295 were also recruited to provide care to patients with COVID-19 (25). Recognizing the risk of  
296 healthcare workers shortages and ensuring them to have adequate rest and to feel supported are  
297 important to maintain individual and team performance in overcoming challenges presented by  
298 COVID-19 (24).

299 There are a number of limitations in this study that need to be acknowledged. Firstly, some factors  
300 had to be excluded due to incomplete data such as malaria prevalence and BCG vaccination.  
301 Secondly, the years from which the data was collected were not consistent for all indicators.  
302 Thirdly, the data collected were not from the same year for one indicator such as the number of  
303 hospital beds. Lastly, some required data were unavailable to sufficiently make an overall  
304 conclusion for some of the factors, including comorbidities. There were 4 other proposed  
305 comorbidities to be analyzed but only two indicators' datasets were available in World Bank Data,  
306 which are diabetes and smoking prevalence. Therefore, more research should be conducted to



307 further understand the relationship between comorbidities and CFR. This would help to identify  
308 and to better understand other possible factors that may also affect CFR.

### 309 **Conclusion**

310 As COVID-19 is such a new disease, much still needs to be learned about it. Age is a clear risk  
311 factor for severe COVID-19 and death. COVID-19 is an illness that disproportionately impacts  
312 older people. However, aforementioned risk factors should not be neglected as they may play  
313 essential roles in flattening the curve and reducing healthcare burden. Prediction alone is not  
314 efficient, but well-planned and suitable interventions should also be carried out. In addition to that,  
315 potential risk factors need a lot more research in order to understand the risks for the worst forms  
316 of COVID-19 and what we ought to learn to best protect the most vulnerable people. Participation  
317 and involvement of every individual, including patients, public and healthcare professionals, is  
318 necessary and everyone should work together towards combating COVID-19 disease.

### 319 **Conflict of interest**

320 None declared.

### 321 **Funding**

322 None.

### 323 **Author contribution**

324 LCM conceived the project. HPG, WIM, NIA, LLC, LCM analyzed results and interpreted the  
325 data and wrote the manuscript draft. NK, BHG, SFY revised the manuscript. All authors read and  
326 approved the final manuscript.

327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346

347 **References**

- 348 1. World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report - 22  
349 [Internet]. [cited 2020 May 5]. Available from: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2)  
350 [source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2)
- 351 2. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC,  
352 Memish Z, Oh M don, Sall AA, et al. COVID-19: towards controlling of a pandemic.  
353 *Lancet* (2020) **395**:1015–1018. doi:10.1016/S0140-6736(20)30673-5
- 354 3. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report 73  
355 [cited 2020 May 5]; Available from: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-)  
356 [source/coronaviruse/who-china-joint-mission-on-covid-19-final-](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-)
- 357 4. Q&A: Similarities and differences – COVID-19 and influenza [Internet]. [cited 2020 Apr  
358 14]. Available from: [https://www.who.int/news-room/q-a-detail/q-a-similarities-and-](https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza)  
359 [differences-covid-19-and-influenza](https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza)
- 360 5. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A  
361 Clinical-Therapeutic Staging Proposal. *J Hear Lung Transplant* (2020) **0**:  
362 doi:10.1016/j.healun.2020.03.012
- 363 6. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G,  
364 Thompson H, Walker PGT, Fu H, et al. Articles Estimates of the severity of coronavirus  
365 disease 2019: a model-based analysis. *Lancet Infect Dis* (2020) doi:10.1016/S1473-  
366 3099(20)30243-7
- 367 7. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation  
368 between universal BCG vaccination policy and reduced mo. *medRxiv*  
369 (2020)2020.03.24.20042937. doi:10.1101/2020.03.24.20042937
- 370 8. Moran KR, Del Valle SY. A meta-analysis of the association between gender and  
371 protective behaviors in response to respiratory epidemics and pandemics. *PLoS One*  
372 (2016) **11**: doi:10.1371/journal.pone.0164541
- 373 9. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical  
374 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:  
375 a retrospective cohort study. *Lancet* (2020) **395**:1054–1062. doi:10.1016/S0140-  
376 6736(20)30566-3
- 377 10. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL,  
378 Pipavath S, Wurfel MM, Evans L, et al. Covid-19 in Critically Ill Patients in the Seattle  
379 Region — Case Series. *N Engl J Med* (2020) doi:10.1056/nejmoa2004500
- 380 11. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, et al.  
381 Clinical characteristics of 113 deceased patients with coronavirus disease 2019:  
382 Retrospective study. *BMJ* (2020) **368**: doi:10.1136/bmj.m1091
- 383 12. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DS, et al. Clinical  
384 characteristics of 2019 novel coronavirus infection in China. *N Engl J Med*  
385 (2020)2020.02.06.20020974. doi:10.1101/2020.02.06.20020974

- 386 13. Some COVID-19 vs. Malaria Numbers: Countries with Malaria have Virtually no  
387 Coronavirus Cases Reported, Roy Spencer [Internet]. [cited 2020 May 5]. Available from:  
388 [https://www.drroyspencer.com/2020/03/some-covid-19-vs-malaria-numbers-countries-](https://www.drroyspencer.com/2020/03/some-covid-19-vs-malaria-numbers-countries-with-malaria-have-virtually-no-coronavirus-cases-reported/)  
389 [with-malaria-have-virtually-no-coronavirus-cases-reported/](https://www.drroyspencer.com/2020/03/some-covid-19-vs-malaria-numbers-countries-with-malaria-have-virtually-no-coronavirus-cases-reported/)
- 390 14. Novel Coronavirus (COVID-19) Cases Data - Humanitarian Data Exchange [Internet].  
391 [cited 2020 May 5]. Available from: [https://data.humdata.org/dataset/novel-coronavirus-](https://data.humdata.org/dataset/novel-coronavirus-2019-ncov-cases)  
392 [2019-ncov-cases](https://data.humdata.org/dataset/novel-coronavirus-2019-ncov-cases)
- 393 15. World Bank Open Data | Data [Internet]. [cited 2020 May 5]. Available from:  
394 <https://data.worldbank.org/>
- 395 16. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al.  
396 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus  
397 pneumonia in Wuhan, China: a descriptive study. *Lancet* (2020) **395**:507–513.  
398 doi:10.1016/S0140-6736(20)30211-7
- 399 17. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'donnell L, Chernyak Y, Tobin KA,  
400 Cerfolio RJ, Francois F, Horwitz LI, et al. Title: Factors associated with hospitalization  
401 and critical illness among 4,103 patients with. doi:10.1101/2020.04.08.20057794
- 402 18. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y.  
403 Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A  
404 systematic review and meta-analysis. *Int J Infect Dis* (2020) **94**:91–95.  
405 doi:10.1016/j.ijid.2020.03.017
- 406 19. Condon BJ, Sinha T. Who is that masked person: The use of face masks on Mexico City  
407 public transportation during the Influenza A (H1N1) outbreak. *Health Policy (New York)*  
408 (2010) **95**:50–56. doi:10.1016/j.healthpol.2009.11.009
- 409 20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al.  
410 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.  
411 *Lancet* (2020) **395**:497–506. doi:10.1016/S0140-6736(20)30183-5
- 412 21. Coronavirus Disease 2019 (COVID-19): Epidemiology, Clinical Spectrum and  
413 Implications for the Cardiovascular Clinician - American College of Cardiology.
- 414 22. Hick JL, Biddinger PD. Novel Coronavirus and Old Lessons - Preparing the Health  
415 System for the Pandemic. *N Engl J Med* (2020) doi:10.1056/NEJMp2005118
- 416 23. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators  
417 and Personal Protective Equipment during the Covid-19 Pandemic. *N Engl J Med* (2020)  
418 doi:10.1056/NEJMp2006141
- 419 24. Adams JG, Walls RM. Supporting the Health Care Workforce during the COVID-19  
420 Global Epidemic. *JAMA - J Am Med Assoc* (2020) **323**:1439–1440.  
421 doi:10.1001/jama.2020.3972
- 422 25. Liu ( Q, Yang J, Liu Q, Luo D, Wang XQ, Phd Y, Yang BX, Yang J, Liu Q, Luo D, et al.  
423 The experiences of health-care providers during the COVID-19 crisis in China: a  
424 qualitative study. *Lancet Glob Heal* (2020) **0**: doi:10.1016/S2214-109X(20)30204-7


425 Table 1: Percentage of confirmed CFR and COVID-19 cases (In sequence of the highest to lowest  
426 CFR%)

No.	Countries	Confirmed COVID-19 cases (%)	Case Fatality Rate (%)
1	Belgium	0.3	13.95
2	United Kingdom	0.15	13.82
3	Italy	0.27	13.11
4	France	0.2	12.77
5	Netherlands	0.17	11.32
6	Sweden	0.12	10.63
7	Spain	0.39	10.46
8	Indonesia	0.002	8.99
9	Mexico	0.005	7.68
10	Philippines	0.01	6.4
11	Iran	0.1	6.24
12	Brazil	0.01	6.07
13	Dominican Republic	0.03	5.23
14	Romania	0.04	5.09
15	Ecuador	0.05	4.94
16	United States	0.2	4.85
17	Switzerland	0.31	4.8
18	Denmark	0.12	4.54
19	Colombia	0.01	4.22
20	China	0.01	4.01
21	Poland	0.02	3.76
22	Canada	0.08	3.56
23	Ireland	0.26	3.54
24	India	0.001	3.4
25	Portugal	0.18	3.33
26	Germany	0.1	2.86
27	Ukraine	0.01	2.79
28	Panama	0.09	2.75
29	Austria	0.16	2.73
30	Czech Republic	0.06	2.63
31	Finland	0.06	2.23
32	Norway	0.13	2.21
33	Peru	0.04	2.21
34	Turkey	0.08	2.19
35	Korea, Rep	0.02	2.16
36	Japan	0.01	2.06
37	Luxembourg	0.56	2.05
38	Serbia	0.07	2.03
39	Pakistan	0.003	1.85
40	Thailand	0.004	1.72
41	Malaysia	0.02	1.62
42	Saudi Arabia	0.02	1.3
43	Chile	0.04	1.14
44	Israel	0.14	1.11
45	Australia	0.03	0.97
46	Belarus	0.04	0.95
47	Russian Federation	0.02	0.83
48	United Arab Emirates	0.06	0.62
49	Singapore	0.07	0.27
50	Qatar	0.15	0.17

427 Table 2: Correlation between different risk factors and COVID-19 CFR

Independent variable		$\beta$ estimate (95% CI)	Standard Errors	P-value
Age (above 65 years)		4.70 (0.34, 9.06)	2.17	<b>0.035</b>
Gender - Male		-0.33 (-0.92, 0.26)	0.29	0.26
Diabetes Prevalence (%)	<b>3.1, 5.5</b>	<b>1.0</b>		0.19
	<b>5.6, 6.94</b>	-0.52 (-1.31, 0.27)	0.39	
	<b>6.95, 9.66</b>	-0.70 (-1.45, 0.05)	0.37	0.07
	<b>9.67, 19.9</b>	-0.93 (-1.66, -0.19)	0.36	<b>0.01</b>
Smoking Prevalence (total % of people aged 15 and above)		0.009(-0.03, 0.04)	0.02	0.60
Current Health Expenditure per capita (US\$)	<b>44, 462</b>	<b>1.0</b>	0.40	0.984
	<b>463, 1429</b>	0.008 (-0.80, 0.82)		
	<b>1430, 4479</b>	0.49 (-0.32, 1.30)	0.40	0.228
	<b>4480, 10200</b>	0.46 (-0.33, 1.25)	0.39	0.248
Hospital Beds (per 1,000 people)		-0.097 (-0.39, 0.19)	0.14	0.50
Nurses and Midwives (per 1,000 people)	<b>0.23, 2.6</b>	<b>1.0</b>	0.41	0.90
	<b>2.7, 6.48</b>	0.05 (-0.78, 0.88)		
	<b>6.49, 10.1</b>	0.07 (-0.76, 0.90)	0.41	0.86
	<b>10.2, 18.2</b>	0.18 (-0.64, 0.99)	0.40	0.67

428  
429  
430  
431  
432  
433  
434  
435  
436



437

438

439 Figure 1: Correlation between case fatality rate and proportion of people aged 65 and above

440